Diane van der Woude

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1495627/publications.pdf

Version: 2024-02-01

88 papers	4,559 citations	136885 32 h-index	106281 65 g-index
89 all docs	89 docs citations	89 times ranked	4938 citing authors

#	Article	IF	Citations
1	Response to: â€˜Correspondence on â€˜Onset of rheumatoid arthritis after COVID-19: coincidence or connected?â€™â€™ by Roongtaet al. Annals of the Rheumatic Diseases, 2023, 82, e137-e137.	0.5	9
2	NT-proBNP and sRAGE levels in early rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2023, 52, 243-249.	0.6	2
3	Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA. Annals of the Rheumatic Diseases, 2022, 81, 141-143.	0.5	11
4	From phenotype to pathophysiologyâ€"placing rheumatic diseases in an immunological perspective. Lancet Rheumatology, The, 2022, 4, e166-e167.	2.2	5
5	DOP27 Humoral immune response after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases treated with immunosuppressive therapy - a Target to B! study. Journal of Crohn's and Colitis, 2022, 16, i079-i079.	0.6	2
6	IgG Antiâ€"Citrullinated Protein Antibody Variable Domain Glycosylation Increases Before the Onset of Rheumatoid Arthritis and Stabilizes Thereafter: A Crossâ€Sectional Study Encompassing ~1,500 Samples. Arthritis and Rheumatology, 2022, 74, 1147-1158.	2.9	23
7	Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases. BMC Medicine, 2022, 20, 100.	2.3	15
8	Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatology, The, 2022, 4, e338-e350.	2.2	88
9	In rheumatoid arthritis patients, total IgA1 and IgA2 levels are elevated: implications for the mucosal origin hypothesis. Rheumatology, 2022, 62, 407-416.	0.9	6
10	Cross-reactivity of anti-modified protein antibodies is also present in predisease and individuals without rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 1332-1334.	0.5	0
11	Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. Lancet Rheumatology, The, 2022, 4, e417-e429.	2.2	33
12	Anti-citrullinated protein antibodies dominate the association of long-term outcomes and anti-modified protein antibodies in rheumatoid arthritis. Lancet Rheumatology, The, 2022, 4, e316-e317.	2.2	3
13	From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis. Nature Reviews Rheumatology, 2022, 18, 371-383.	3.5	32
14	Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 921-930.	2.9	17
15	Onset of rheumatoid arthritis after COVID-19: coincidence or connected?. Annals of the Rheumatic Diseases, 2021, 80, 1096-1098.	0.5	53
16	Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications. Arthritis Research and Therapy, 2021, 23, 298.	1.6	5
17	Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology. Immunological Reviews, 2020, 294, 148-163.	2.8	86
18	Secretory form of rheumatoid arthritisâ€"associated autoantibodies in serum are mainly of the IgM isotype, suggesting a continuous reactivation of autoantibody responses at mucosal surfaces. Annals of the Rheumatic Diseases, 2019, 78, 146-148.	0.5	22

#	Article	IF	Citations
19	In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. Arthritis Research and Therapy, 2019, 21, 28.	1.6	33
20	Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification. Annals of the Rheumatic Diseases, 2019, 78, 908-916.	0.5	34
21	Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12â€‰months of tapering anti-rheumatic drugs. Arthritis Research and Therapy, 2019, 21, 268.	1.6	19
22	Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis. Rheumatology, 2019, 58, 149-153.	0.9	11
23	Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors. Cancer Immunology Research, 2019, 7, 6-11.	1.6	118
24	Baseline autoantibody profile in rheumatoid arthritisÂis associated with early treatment response but not long-term outcomes. Arthritis Research and Therapy, 2018, 20, 33.	1.6	39
25	Comment on â€œ Aggregatibacter actinomycetemcomitans â€“induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritisâ€• Science Translational Medicine, 2018, 10, .	5.8	24
26	Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 174-187.	1.4	289
27	Triple Positivity for Antiâ€“Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Antiâ€“Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1721-1731.	2.9	81
28	Antiâ€“Carbamylated Protein Antibodies and Higher Baseline Disease Activity in Rheumatoid Arthritisâ€”A Replication Study in Three Cohorts: Comment on the Article by Truchetet et al. Arthritis and Rheumatology, 2018, 70, 2096-2097.	2.9	6
29	In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission. Annals of the Rheumatic Diseases, 2018, 77, 1836-1838.	0.5	12
30	Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present. Annals of the Rheumatic Diseases, 2017, 76, 716-720.	0.5	35
31	Long-term mortality in patients with ST-segment elevation myocardial infarction is associated with anti-citrullinated protein antibodies. International Journal of Cardiology, 2017, 240, 20-24.	0.8	11
32	The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Seminars in Immunopathology, 2017, 39, 437-446.	2.8	203
33	The contribution of autoantibodies to post-translationally modified proteins to inflammatory arthritis. Current Opinion in Rheumatology, 2017, 29, 195-200.	2.0	0
34	Antibodies against collagen type II are not a general marker of acute arthritis onset. Annals of the Rheumatic Diseases, 2017, 77, annrheumdis-2017-211974.	0.5	4
35	Molecular basis for increased susceptibility of Indigenous North Americans to seropositive rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1915-1923.	0.5	36
36	The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. Arthritis Research and Therapy, 2017, 19, 190.	1.6	20

#	Article	IF	Citations
37	The role of anticitrullinated protein antibodies in the early stages of rheumatoid arthritis. Current Opinion in Rheumatology, 2016, 28, 275-281.	2.0	18
38	The target of ACPA. Rheumatology, 2016, 55, 1711-1713.	0.9	2
39	Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. Arthritis Research and Therapy, 2016, 18, 285.	1.6	43
40	Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammation. Annals of the Rheumatic Diseases, 2016, 75, 1575-1576.	0.5	32
41	A2.10â€...The isotype and subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2016, 75, A19.1-A19.	0.5	0
42	SAT0085â€...Do Specific Acpas or Other Autoantibodies Measured by A Novel Assay Predict Response To Methotrexate Monotherapy in Patients with Early Dmard-NaÃ¯ve Ra?. Annals of the Rheumatic Diseases, 2016, 75, 696.1-696.	0.5	0
43	Protective effect of HLA-DRB1*13 alleles during specific phases in the development of ACPA-positive RA. Annals of the Rheumatic Diseases, 2016, 75, 1891-1898.	0.5	12
44	HLA and anti-citrullinated protein antibodies: Building blocks in RA. Best Practice and Research in Clinical Rheumatology, 2015, 29, 692-705.	1.4	12
45	An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting. Arthritis Research and Therapy, 2015, 17, 276.	1.6	21
46	Marginal Genetic Effects Estimation in Family and Twin Studies Using Random-Effects Models. Biometrics, 2015, 71, 1130-1138.	0.8	8
47	Crossreactivity to vinculin and microbes provides a molecular basis for HLA-based protection against rheumatoid arthritis. Nature Communications, 2015, 6, 6681.	5.8	66
48	Fine-mapping the human leukocyte antigen locus in rheumatoid arthritis and other rheumatic diseases. Current Opinion in Rheumatology, 2015, 27, 256-261.	2.0	14
49	How undifferentiated arthritis evolves into chronic arthritis. Best Practice and Research in Clinical Rheumatology, 2014, 28, 551-564.	1.4	3
50	Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Annals of the Rheumatic Diseases, 2014, 73, 1761-1768.	0.5	111
51	HLA and rheumatoid arthritis: How do they connect?. Annals of Medicine, 2014, 46, 304-310.	1.5	26
52	Pathogenic relevance of anti-citrullinated vimentin antibodies: Comment on the article by Montes et al. Arthritis and Rheumatism, 2013, 65, 541-542.	6.7	0
53	Editorial: Family Studies in the Information Age. Arthritis and Rheumatism, 2013, 65, 2762-2764.	6.7	0
54	Patients with early arthritis consume less alcohol than controls, regardless of the type of arthritis. Rheumatology, 2013, 52, 1701-1707.	0.9	14

#	Article	IF	Citations
55	The contribution of genetic risk factors other than the HLA shared epitope alleles to the genetic variance of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, A52.1-A52.	0.5	0
56	Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology, 2012, 51, 1120-1128.	0.9	38
57	Combining Family and Twin Data in Association Studies to Estimate the Noninherited Maternal Antigens Effect. Genetic Epidemiology, 2012, 36, 811-819.	0.6	2
58	The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. Arthritis and Rheumatism, 2011, 63, 1823-1832.	6.7	55
59	Distinct ACPA fine-specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, A5-A5.	0.5	0
60	Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Annals of the Rheumatic Diseases, 2011, 70, 188-193.	0.5	118
61	Genetics of ACPA-positive rheumatoid arthritis: the beginning of the end?. Annals of the Rheumatic Diseases, 2011, 70, i51-i54.	0.5	32
62	Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 1461-1464.	0.5	45
63	Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens. Annals of the Rheumatic Diseases, 2011, 70, 373-379.	0.5	69
64	ACPA (anti-citrullinated protein antibodies) and rheumatoid arthritis. Acta ReumatolÃ³gica Portuguesa, 2011, 36, 205-7.	0.2	6
65	Protection against antiâ€“citrullinated protein antibodyâ€“positive rheumatoid arthritis is predominantly associated with HLAâ€“DRB1*1301: A metaâ€analysis of HLAâ€“DRB1 associations with antiâ€“citrullinated protein antibodyâ€“positive and antiâ€“citrullinated protein antibodyâ€“negative rheumatoid arthritis in four European populations. Arthritis and Rheumatism, 2010, 62, 1236-1245.	6.7	135
66	Glycan profiling of antiâ€“citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis and Rheumatism, 2010, 62, 1620-1629.	6.7	183
67	Longâ€term impact of delay in assessment of patients with early arthritis. Arthritis and Rheumatism, 2010, 62, 3537-3546.	6.7	357
68	Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis. Nature Genetics, 2010, 42, 814-816.	9.4	65
69	Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1554-1561.	0.5	268
70	Anti-citrullinated protein antibodies have a low avidity compared to antibodies against recall-antigens. Annals of the Rheumatic Diseases, 2010, 69, A7-A7.	0.5	0
71	Anti-CCP antibodies are a collection of ACPA that are cross-reactive to multiple citrullinated antigens. Annals of the Rheumatic Diseases, 2010, 69, A8-A8.	0.5	3
72	The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1110-1116.	0.5	68

#	Article	IF	Citations
73	Antibodies toPorphyromonas gingivalisAre Associated with Anticitrullinated Protein Antibodies in Patients with Rheumatoid Arthritis and Their Relatives. Journal of Rheumatology, 2010, 37, 1105-1112.	1.0	195
74	Every shared epitope allele for itself?. Nature Reviews Rheumatology, 2009, 5, 477-478.	3.5	2
75	Quantitative heritability of antiâ€“citrullinated protein antibodyâ€“positive and antiâ€“citrullinated protein antibodyâ€“negative rheumatoid arthritis. Arthritis and Rheumatism, 2009, 60, 916-923.	6.7	200
76	Antiâ€“cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis and Rheumatism, 2009, 60, 1923-1931.	6.7	212
77	Prevalence of and predictive factors for sustained diseaseâ€modifying antirheumatic drugâ€“free remission in rheumatoid arthritis: Results from two large early arthritis cohorts. Arthritis and Rheumatism, 2009, 60, 2262-2271.	6.7	193
78	Value of antiâ€“modified citrullinated vimentin and thirdâ€generation antiâ€“cyclic citrullinated peptide compared with secondâ€generation antiâ€“cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis and Rheumatism, 2009, 60, 2232-2241.	6.7	138
79	Immunoglobulin 1 (IgG1) Fcâ€glycosylation profiling of antiâ€citrullinated peptide antibodies from human serum. Proteomics - Clinical Applications, 2009, 3, 106-115.	0.8	33
80	Marked differences in fine specificity and isotype usage of the antiâ€“citrullinated protein antibody in health and disease. Arthritis and Rheumatism, 2008, 58, 3000-3008.	6.7	156
81	Translating basic research into clinical rheumatology. Best Practice and Research in Clinical Rheumatology, 2008, 22, 299-310.	1.4	6
82	The battle between anti-cyclic citrullinated peptide and rheumatoid factor testsâ€”a winner at last?. Nature Clinical Practice Rheumatology, 2007, 3, 696-697.	3.2	1
83	Bariatric Surgery and Mortality. New England Journal of Medicine, 2007, 357, 2633-2634.	13.9	3
84	Cutting Edge: Inducible Costimulator Protein Regulates Both Th1 and Th2 Responses to Cutaneous Leishmaniasis. Journal of Immunology, 2002, 168, 991-995.	0.4	56
85	CTLA-4 regulates cell cycle progression during a primary immune response. European Journal of Immunology, 2002, 32, 366-373.	1.6	115
86	T helper differentiation in resistant and susceptible B7-deficient mice infected with Leishmania major. European Journal of Immunology, 2002, 32, 1764.	1.6	22
87	Modulation of IFN-??-induced immunogenicity by phosphatidylethanolamine-linked hyaluronic acid1. Transplantation, 2002, 73, 984-992.	0.5	12
88	Presence of SARS-CoV-2 antibodies in patients with COVID-19 like symptoms from the IENIMINI cohort. Scandinavian Journal of Rheumatology, 0, , 1-4.	0.6	0